Surgical outcomes from the Phase III CheckMate 816 trial

Dr. Patrick Forde Discusses 3-Year CheckMate 816 NSCLC Results at ASCO 2023Подробнее

ASCO 2021 Lung Recap: Surgical Outcomes & Checkmate 816: Nivolumab in Early Stage NSCLCПодробнее

Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLCПодробнее

Dr KRIPA BAJAJ | SURGICAL OUTCOMES FROM THE PHASE 3 CHECKMATE 816 TRIAL Update 19 February 2022Подробнее

Surgical outcomes from CheckMate 816: NIVO plus chemo vs chemo alone as neoadjuvant treatment fo...Подробнее

CheckMate 816 trial: Nivolumab + platinum-doublet chemotherapy vs chemo as neoadjuvant treatment...Подробнее

CheckMate 816: addressing unanswered questions on surgical outcomes following neoadjuvant chemo-IOПодробнее